Major Investor Fairmount Funds Sells $300M in Oruka Therapeutics Stock
ORKA has more than doubled off its 52-week low of $10.966.
Summary
Fairmount Funds Management LLC, a major institutional investor, sold approximately $300 million worth of Oruka Therapeutics common stock in a block trade after converting preferred shares.
Key Events · Ownership and Investor Activity · ORKA
-
Major Investor Sells Significant Stake
Fairmount Funds Management LLC, a 10% owner, sold 3,553,410 shares of common stock in a block trade.
-
$300 Million Transaction Value
The shares were sold at $84.43 per share, totaling approximately $300 million.
-
Conversion of Preferred Stock Preceded Sale
The sale followed the conversion of 42,641 shares of Series B Preferred Stock into the common stock sold.
-
Reduced Ownership
The reporting persons' aggregate beneficial ownership is now 19.47% of the outstanding common stock.
Analysis · ORKA · Life Sciences
Fairmount Funds Management LLC, a significant institutional investor, executed a block trade selling 3.55 million shares of Oruka Therapeutics common stock for approximately $300 million. This sale represents a substantial reduction of their stake, following the conversion of preferred stock into common shares. Such a large disposition by a major investor can signal a shift in their investment thesis or a need for liquidity, potentially creating downward pressure on the stock.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ORKA was trading at $86.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $10.97 to $97.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.